CoChat

Enhancement of insulin‐stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone

Hällsten, K., Virtanen, K. A., Lönnqvist, F., Janatuinen, T., Turiceanu, M., Rönnemaa, T., Viikari, J., Lehtimäki, T., Knuuti, J., Nuutila, P. · 2004 · Diabetic Medicine
Cited by 89

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims Peroxisome proliferator‐activated receptor γ (PPARγ) activators have recently been identified as regulators of cellular proliferation, inflammatory responses and lipid and glucose metabolism. These agents prevent coronary arteriosclerosis and improve left ventricular remodelling and function in heart failure after myocardial infarction. Improvement in myocardial metabolic state may be one of the mechanisms behind these findings. The aim of this study was to investigate the effects of rosiglitazone on myocardial glucose uptake in patients with Type 2 diabetes. Placebo and metformin were used as control treatments. Methods Forty‐four patients were randomized to treatment with rosiglitazone (4 mg b.i.d.), metformin (1 g b.i.d.) or placebo in a 26‐week double‐blinded trial. Myocardial glucose uptake was measured using [18 F]‐2‐fluoro‐2‐deoxy‐D‐glucose ([18 F]FDG) and positron emission tomography (PET) during euglycaemic hyperinsulinaemia before and after the treatment. Results Rosiglitazone increased insulin‐stimulated myocardial glucose uptake by 38% (from 38.7 ± 3.4 to 53.3 ± 3.6 µmol 100 g−1 min−1, P = 0.004) and whole body glucose uptake by 36% (P = 0.01), while metformin treatment had no significant effect on myocardial (40.5 ± 3.5 vs. 36.6 ± 5.2, NS) or whole body glucose uptake. Myocardial work as determined by the rate‐pressure‐product was similar between the groups. Neither treatment had any significant effect on fasting serum free fatty acids (FFA) but the FFA levels during hyperinsulinaemia were more suppressed in the rosiglitazone group (−47%, P = 0.02). Myocardial glucose uptake correlated inversely to FFA concentrations both before (r =−0.54, P = 0.002) and after (r = −0.43, P = 0.01) the treatment period in the pooled data. Furthermore, the increase in myocardial glucose uptake correlated inversely with interleukin‐6 (IL‐6) concentrations (r = −0.58, P = 0.03). Conclusions In addition to the improvement in whole body insulin sensitivity, rosiglitazone treatment enhances insulin stimulated myocardial glucose uptake in patients with Type 2 diabetes, most probably due to its suppression of the serum FFAs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2004.01332.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 89

Metadata

Authors
Hällsten, K., Virtanen, K. A., Lönnqvist, F., Janatuinen, T., Turiceanu, M., Rönnemaa, T., Viikari, J., Lehtimäki, T., Knuuti, J., & Nuutila, P.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2004-11-24
Volume
21
Issue
12
Pages
1280-1287
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2111410515
Cited by
89
References
9
FWCI
2.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancement of insulin‐stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. https://app.cochat.ai/papers/10.1111/j.1464-5491.2004.01332.x
The paper
Hällsten, K., Virtanen, K. A., Lönnqvist, F., Janatuinen, T., Turiceanu, M., Rönnemaa, T., Viikari, J., Lehtimäki, T., Knuuti, J., & Nuutila, P. (2004). Enhancement of insulin‐stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2004.01332.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.